Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Microbot MedicalMBOT 21 Days Sales Outstanding is 53.20 as of Jun. 2026. GuruFocus rates MBOT with a GF Score™ of 21/100. The stock has 3 warning signs investors should review. Among 809 Medical Devices & Instruments companies, Microbot Medical ranks worse than 89.74% on this metric.
The historical rank and industry rank for Microbot Medical's Days Sales Outstanding or its related term are showing as below:
MBOT'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 0 Med: 0 Max: 148.22
Current: 148.22
During the past 13 years, Microbot Medical's highest Days Sales Outstanding was 148.22. The lowest was 0.00. And the median was 0.00.
MBOT's Days Sales Outstanding is ranked worse than 89.74% of 809
companies
in the Medical Devices & Instruments industry
Industry Median: 64.94
vs MBOT: 148.22
Microbot Medical's Days Sales Outstanding
increased
from Jun. 2025 (0.00) to Jun. 2026 (53.20).
Microbot Medical (NAS:MBOT) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Microbot Medical Days Sales Outstanding Related Terms
Microbot Medical Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Microbot Medical's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MBOT vs LNSR, LUNG, ECOR: Days Sales Outstanding Comparison
For the Medical Devices subindustry, Microbot Medical's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Microbot Medical Days Sales Outstanding vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Microbot Medical's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Microbot Medical's Days Sales Outstanding falls into.
Microbot Medical Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Microbot Medical (MBOT) has a Days Sales Outstanding of 53.20 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Microbot Medical and its competitors. According to the industry distribution chart, Microbot Medical ranks #726 out of 809 companies in the Medical Devices & Instruments industry, placing it in the top 89.7%.
Is Microbot Medical's Days Sales Outstanding too high?
Microbot Medical's current Days Sales Outstanding is 53.20. The Medical Devices & Instruments industry median Days Sales Outstanding is 64.94. Microbot Medical's value of 53.20 is 18.1% below this industry median. Based on the distribution chart, Microbot Medical ranks #726 out of 809 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Microbot Medical has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Microbot Medical's Days Sales Outstanding compare to LNSR and LUNG?
According to the Medical Devices & Instruments industry distribution chart, Microbot Medical ranks #726 out of 809 companies for Days Sales Outstanding. This places Microbot Medical in the lower half of its industry. The industry median Days Sales Outstanding is 64.94. Microbot Medical's value of 53.20 is 18.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Devices & Instruments company?
The median Days Sales Outstanding among Medical Devices & Instruments companies is 64.94, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Microbot Medical's current Days Sales Outstanding of 53.20 is 18.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Microbot Medical and its competitors. For the Medical Devices & Instruments industry, the median Days Sales Outstanding is 64.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Microbot Medical's current Days Sales Outstanding is 53.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Microbot Medical stock overvalued right now?
Microbot Medical (MBOT) has a current Days Sales Outstanding of 53.20. The current Days Sales Outstanding is 53.20 and 18.1% below the Medical Devices & Instruments industry median of 64.94. Microbot Medical's overall GF Score™ is 21/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Microbot Medical (MBOT), the current Days Sales Outstanding is 53.20 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Microbot Medical Inc is a medical device company specializing in the research, design, and development of next-generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. Using its LIBERTY technological platform, the company has developed the LIBERTY Endovascular Robotic Surgical System, a fully disposable robot for various endovascular interventional procedures. The company has a single operating and reportable segment, which is the development of robotic devices for endoluminal surgery.
21GF Score
Get the complete analysis for MBOT
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MBOT has been successfully added to your 
